Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.

Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.